Pricing Log in Create free account
Friday 6 November 2026 Export OGI’s income statement to Excel — free account

Organigram Global Inc.

OGI Healthcare Drug Manufacturers Specialty & Generic

Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024.

Revenue
+49.3%
EPS
+1,966.7%
Free cash flow
−192.3%

Quarter to June 2026, against a year earlier

0.88 0.05 −5.38%
Market cap
$131.1M
P/E
2.0×
Fwd P/E
1.6×
Dividend yield
—
F-score
5/9
Altman Z
0.22
Beneish M
−1.82
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 28.20%

Capital & Financial Ratios $m

Size
Market Cap 131.11
Revenue ttm 223.47
Net income ttm 62.74
Free cash flow ttm (21.14)
Net debt Q 6.72
Valuation
P/E 2.02
Forward P/E 1.64
Price / sales 0.57
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.36
Financial health
Current ratio Q 2.61 (at or above 1.5: strong)
Debt / equity Q 0.04 (at or below 0.5: strong)
Interest coverage Q (101.72)
Growth
Revenue growth Q +49.28% (above 0%: growing)
Operating income growth Q +293.00% (above 0%: growing)
EPS, this year +525.54% (at or above 15%: strong)
EPS, next year A −92.19% (below 0%: weak)
Revenue, next year A +34.85% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of 2.1×; over the ten years it ranged from 0.4× in 2024 to 20.8× in 2019.
P/S against its own 10 years 1.55%
10-year low 10-year high
P/B against its own 10 years 1.46%
10-year low 10-year high
EV/Sales against its own 10 years 8.93%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 25 98 60 8
Receivables 22 27 46 64
Inventory 60 61 89 119
Other 8 7 8 11
116 193 204 202
2023 2024 2025 Q'26
Payables 15 35 64 72
ST’ Debt 1 — — 2
Other 1 5 26 3
17 39 90 77

Compound Annual Growth %

10y 5y 3y
Sales 45.89% 24.30% 18.80%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 14.34% (7.99%) 7.45%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate −0.01 Actual −0.05

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 −0.01 −0.20 Miss by 0.19
Dec 2025 −0.01 −0.02 Miss by 0.01
Mar 2026 −0.01 −0.01 Met by 0.00
Jun 2026 −0.01 −0.05 Miss by 0.04
Sep 2026 0.02 — Reports 15 December 2026

EPS $

Dec Mar Jun Sep Year
’26 0.11 (0.01) 0.56 — —
’25 (0.14) 0.26 (0.03) (0.20) (0.14)
’24 (0.14) (0.22) 0.02 (0.04) (0.35)
’23 — — — (0.32) (2.27)
’23 — — — — (2.09)
’22 — — — — (0.15)
’21 — — — — (1.54)
Fiscal quarters ending in the months shown.

Revenue $m

Dec Mar Jun Sep Year
’26 46 44 76 — —
’25 31 46 51 58 185
’24 27 28 30 33 117
’23 — — — 34 120
’23 — — — — 111
’22 — — — — 115
’21 — — — — 62
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 (11) (5) (3) — —
’25 (3) (11) 10 (1) (5)
’24 6 (7) (3) 7 3
’23 — — — (13) (29)
’23 — — — — (26)
’22 — — — — (28)
’21 — — — — (23)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 (13) (5) (3) — —
’25 (4) (16) 3 0 (18)
’24 5 (7) (3) 5 (1)
’23 — — — (18) (51)
’23 — — — — (26)
’22 — — — — (67)
’21 — — — — (32)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 5 10 10 61 65 62 115 120 117 185 223 +50.5% 250 327 348 +23.3%
Gross margin, % 82.08 422.39 422.39 60.28 (65.08) (35.87) 21.65 23.51 29.73 34.81 36.47 (47.3) pt
EBT 1 22 22 (4) (109) (103) (11) (187) (33) (28) 60 n/m
EBT margin, % 13.82 223.48 223.48 (7.31) (168.94) (165.11) (9.86) (156.16) (28.43) (14.87) 26.76 (28.7) pt
Net income 1 0 17 (7) (101) (103) (11) (184) (33) (18) 63 n/m
Per share, $
Per share, $ Revenue 0.08 0.00 0.32 1.72 1.50 0.98 1.48 1.47 1.23 1.45 1.65 +38.0%
Earnings 0.01 (0.09) 0.53 (0.20) (2.35) (1.61) (0.15) (2.27) (0.35) (0.14) 0.46 n/m
Cash flow (0.03) (0.07) (0.33) (0.75) (0.78) (0.35) (0.37) (0.35) 0.03 (0.04) (0.15) +4.7%
Capex 0.00 0.00 (1.47) (2.36) (1.36) (0.15) (0.50) (0.27) (0.04) (0.09) 0.00 n/m
Free cash flow (0.03) (0.07) (1.80) (3.11) (2.13) (0.50) (0.87) (0.62) (0.01) (0.14) (0.16) +19.2%
Book value 0.58 0.00 4.80 7.00 5.16 5.91 5.17 2.48 2.36 1.95 2.59 +14.5%
Shares, m 59 97 30 35 43 64 77 81 95 128 132 +9.0%
Valuation, ×
Valuation, × P/E 169.43 30.04 30.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.02 23.0
P/S 0.00 0.00 0.00 9.99 3.37 10.95 2.88 0.86 1.47 1.40 0.57 3.1
P/B 4.03 4.03 4.03 2.46 0.98 1.81 0.83 0.51 0.77 1.04 0.36 2.0
EV/Sales 0.00 0.00 0.00 10.01 3.84 8.64 2.21 0.65 0.63 1.07 0.60 2.7
EV/FCF 0.00 0.00 0.00 (5.60) (2.69) (16.73) (3.79) (1.55) (71.19) (11.34) (6.33) (11.3)
Cash, $m
Cash, $m Operating cash flow (2) (7) (10) (26) (34) (23) (28) (29) 3 (5) (21) +14.1%
Capex (3) (25) (44) (83) (59) (10) (38) (22) (4) (12) (1) +15.3%
Free cash flow (2) (7) (54) (110) (92) (32) (67) (51) (1) (18) (21) +30.0%
Balance, $m
Balance, $m Working capital 29 150 150 115 105 185 131 99 154 113 125 +16.3%
Net debt (19) (100) (24) 1 30 (145) (77) (25) (98) (60) 7 +13.6%
Shareholders’ equity 34 145 145 247 223 378 399 201 225 250 351 +24.9%
Returns, %
Returns, % ROA 1.13 13.56 6.78 (2.57) (31.31) (27.10) (2.52) (83.34) (12.82) (5.05) 12.70 (6.2) pt
ROIC 0.00 39.65 14.81 1.04 (26.74) (19.35) (6.58) (69.08) (12.92) (3.61) (1.53) (3.6) pt
ROE 1.30 48.70 22.13 (3.68) (43.15) (34.29) (2.89) (91.57) (15.67) (7.46) 20.20 (8.8) pt
People
People Employees — — 479 770 552 736 882 935 914 1,139 — +13.2%
Revenue/emp, $m 0.00 0.00 0.02 0.08 0.12 0.08 0.13 0.13 0.13 0.16 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Organigram Global Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SIGA Siga Technologies Inc. $213.4M — (loss-making) 60.8× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91% Compare
ADCT ADC Therapeutics SA $209.4M — (loss-making) — (loss-making) +2.17% (above 0%: growing) n/m +50.98% (above 0%: growing) 87.80% (132.03%) Compare
GLAS Glass House Brands Inc. $172.7M — (loss-making) — (loss-making) −1.24% (below 0%: shrinking) n/m −123.36% (below 0%: shrinking) 33.54% (6.37%) Compare
OGI Organigram Global Inc. $131.1M 2.0× 1.6× +49.28% (above 0%: growing) n/m −192.32% (below 0%: shrinking) 39.16% 5.04%
BGM BGM Group Ltd. $125.7M 148× 44.9× −2.59% (below 0%: shrinking) −85.71% (below 0%: shrinking) +3.00% (above 0%: growing) 7.12% 0.00% Compare
DERM Journey Medical Corporation $121.4M — (loss-making) — (loss-making) +23.33% (above 0%: growing) n/m −84.08% (below 0%: shrinking) 66.81% 2.46% Compare
AKBA Akebia Therapeutics, Inc. $117.9M — (loss-making) — (loss-making) −37.20% (below 0%: shrinking) n/m −94.20% (below 0%: shrinking) 82.76% (31.06%) Compare
CRDL Cardiol Therapeutics Inc. $111.8M — (loss-making) — (loss-making) — n/m +10.61% (above 0%: growing) 0.00% 0.00% Compare
ORGO Organogenesis $108.1M — (loss-making) — (loss-making) −69.87% (below 0%: shrinking) n/m −2,048.82% (below 0%: shrinking) 51.83% (64.87%) Compare
Median of peers $123.5M — — −2.59% — −80.01% 54.50% (3.18%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Organigram Global Inc. (OGI) Latest News

5 Nov

Impact 4 · · Business Wire

4 Nov

Impact 4 · · Zacks

3 Nov

Impact 4 · · Proactive Investors
Impact 4 · · MT Newswires
Impact 4 · · Stocktwits
Impact 4 · · Moby
Impact 4 · · Business Wire

15 Oct

Impact 4 · · Business Wire

13 Oct

Impact 4 · · Moby

30 Sep

Impact 4 · · MarketBeat
Impact 3 · · Business Wire

20 Aug

Impact 3 ·

18 Aug

Impact 4 · · The Motley Fool transcript

12 Aug

Impact 3 · · Moby transcript

11 Aug

Impact 4 ·
Impact 4 ·
Impact 3 ·
Impact 3 · · MarketBeat

20 Jul

Impact 3 ·

31 May

Impact 4 · · Insider Monkey

13 May

Impact 4 · · Benzinga transcript
Impact 4 · · Benzinga transcript

12 May

Impact 4 · · MarketBeat
Impact 3 · · GuruFocus.com
Impact 3 · · InvestorsHub
Impact 3 · · Zacks
Impact 3 · · MT Newswires
Impact 3 · · Business Wire

17 Apr

Impact 4 · · Insider Monkey

15 Apr

Impact 4 · · Business Wire
stockrow.com/OGI · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com